Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01997268
Other study ID # P-13-009
Secondary ID
Status Withdrawn
Phase Phase 3
First received November 22, 2013
Last updated November 22, 2016

Study information

Verified date November 2016
Source Sancilio and Company, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effects of SC401B (ethyl esters of eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] 2 (~1260 mg EPA+DHA), 4 (~2520 mg EPA+DHA) or 6 (~3780 mg EPA+DHA) capsules per day in subjects with hypertriglyceridemia (triglyceride [TG] ≥500 mg/dL and ≤ 2,000 mg/dL). SC401B capsules also contain certain surfactants that may aid in the absorption of EPA and DHA. Based on the results of pharmacokinetic studies of healthy human subjects, unlike Lovaza®, EPA and DHA in SC401B are bioavailable in both the fasted and fed states.

The protocol specified primary endpoint is the difference from the placebo group in the percent change in TG concentration from baseline to week 12 for groups receiving 2, 4, or 6 capsules of SC401B per day. The protocol specified secondary endpoints include percent changes from baseline to week 12 for total cholesterol (TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), and non-HDL-cholesterol (non-HDL-C). Additional exploratory variables include VLDL-cholesterol (VLDL-C), LDL-cholesterol particle size, apolipoprotein (Apo) A1, Apo B, Apo C-III, and lipoprotein-associated phospholipase A2 (Lp-PLA2).

An additional objective is to determine the tolerability and safety of SC401B 2, 4 and 6 capsules per day for 12 weeks. Adverse events for SC401B and placebo including burping, fishy taste, upset stomach, loose stools, stools with fishy smell or any other self-reported observations will be evaluated. Additional safety measures will include changes in liver enzymes (AST/ALT) occurring from baseline to week 12 for groups receiving 2, 4, and 6 capsules of SC401B and placebo.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Be male or female, age 18 years

- Have a TG level =500 mg/dL and =2,000 mg

- Have the ability to understand the requirements of the study and be willing to provide written informed consent (as evidenced by signature on an informed consent document approved by an Institutional Review Board [IRB]) and agree to abide by the study restrictions and return for the required assessments.

- Be normally active and in good health on the basis of medical history.

- Willing to maintain a stable diet and not alter their physical activity level throughout the study.

- Women of childbearing potential must be willing to use accepted birth control methods throughout the study.

Exclusion Criteria:

- Women who are pregnant, planning to become pregnant, or breastfeed during the study period

- History of pancreatitis

- Hemoglobin A1c > 9.5% (subjects with diabetes mellitus will be required to receive stable therapy)

- History of stroke, myocardial infarction, life-threatening arrhythmia, or coronary vascularization within 6 months before screening

- Thyroid-stimulating hormone > 1.5 x upper limit of normal; clinical evidence of hypothyroidism or thyroid hormonal therapy that has not been stable for

- 6 weeks before screening

- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 x upper limit of normal

- An unexplained creatine kinase concentration > 3 x upper limit of normal or creatine kinase elevation due to known muscle disease (e.g., polymyositis, mitochondrial dysfunction)

- Blood donation of =1 pint within 30 days before screening or plasma donation within 7 days before screening

- The consumption of >2 alcoholic beverages per day after screening; a history of illicit drug use within 1 year before screening

- A history of symptomatic gallstone disease unless treated with cholecystectomy

- Known nephrotic syndrome or >3 g/day proteinuria

- Allergy or intolerance to omega-3 fatty acids, ethyl esters, or fish; known lipoprotein lipase impairment or deficiency or apoC-II deficiency or familial dysbetalipoproteinemia

- History of cancer (other than basal cell carcinoma of the skin) in the past 2 years; and a history or evidence of major and clinically significant disease that could adversely affect the conduct of the study or patient safety.

- Use acetylcholinesterase inhibitors or memantine, in the prior 2 months to screening

- Use of a lipase inhibitor such as Xenical (orlistat)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Corn Oil
SC401B 2 capsules

SC401B 4 capsules

SC401B 6 capsules


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sancilio and Company, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Fasting Serum Triglycerides The primary endpoints are the differences in mean percent changes from baseline to end-of-treatment (12 weeks) in triglyceride levels between placebo and 2, 4, and 6 capsules per day of SC401B. 12 weeks Yes
See also
  Status Clinical Trial Phase
Completed NCT01208961 - Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation Phase 2
Completed NCT04541186 - Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia Phase 2
Active, not recruiting NCT05079919 - A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia Phase 3
Completed NCT02189252 - An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis Phase 1
Active, not recruiting NCT01229566 - Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia Phase 3
Completed NCT03001817 - Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function Phase 3
Completed NCT03011450 - Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment Phase 3
Completed NCT05355402 - A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia Phase 2
Completed NCT04720534 - Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia Phase 2
Recruiting NCT06347003 - Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia Phase 3
Recruiting NCT06347016 - Study of Plozasiran in Adults With Severe Hypertriglyceridemia Phase 3
Withdrawn NCT04662528 - Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL Phase 3
Recruiting NCT05852431 - To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia Phase 3
Completed NCT01242527 - Epanova® for Lowering Very High Triglycerides Phase 2/Phase 3
Completed NCT02944383 - A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia Phase 2
Recruiting NCT05681351 - A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) Phase 3
Recruiting NCT05552326 - A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Phase 3